Thoracic Oncology Program

Smilow Cancer Hospital's Thoracic Oncology Program is a leader in lung cancer treatment and other thoracic malignancies, such as esophageal cancer, thymoma and chest wall tumors. As soon as a new thoracic oncology patient's CT scans, biopsies and other test results are available, Smilow physicians see the patient, review the evidence, discuss the case at the weekly multidisciplinary thoracic tumor board and decide on the best course of treatment based on the collective judgment of the team.

Lung cancer is still a frightening form of cancer, but patients who visit Smilow Cancer Hospital find their options for a good outcome are changing rapidly. Many patients with advanced stage disease are surviving for years with new cutting-edge lung cancer treatments, and physicians are looking toward a future where they can talk about the once fatal disease as a chronic illness.

Three factors are raising the bar on outcomes for patients at Smilow Cancer Hospital:

  • The thoracic oncology program focuses on a collaborative team approach, in which the patient's physician draws upon the collective expertise of the national and international experts at Smilow Cancer Hospital.
  • A focus on evidence-based practice in which physicians employ the latest standards of thoracic oncology treatment.
  • An ongoing commitment to push the forefront through clinical research that is defining better therapy.

Learn more about Smilow Cancer Hospital for thoracic oncology

Innovative Research

Through Yale Cancer Center, our thoracic surgeons and physicians are collaborating with scientists to develop an active, robust translational research effort. General research themes for lung cancer treatment include risk stratification and screening for lung cancer and molecular characterization of lung cancers. Thoracic Oncology Program clinicians are continually sharing insights from the clinic with researchers in laboratories to better focus their efforts. This collaboration creates the best possible innovations for our patients.

Learn more about our research initiatives